FDA’s Plan B Decision To Be Guided By Public Comments, Deputy Commissioner Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is awaiting comments about the “legal authority and regulatory pathway” for marketing an active ingredient both as a prescription and OTC drug, Deputy Commissioner Gottlieb says.